Qelbree (viloxazine) is not an SNRI. It belongs to a distinct pharmacological category called a serotonin-norepinephrine modulating agent, or SNMA. The difference matters because Qelbree affects serotonin and norepinephrine through a fundamentally different mechanism than SNRIs like venlafaxine or duloxetine, and this gives it a unique side effect profile and a specific role in treating ADHD.
Why Qelbree Is Not an SNRI
SNRIs work by directly blocking the reuptake of both serotonin and norepinephrine at the transporter level, keeping more of each chemical active in the brain. Qelbree does something different. It has essentially zero ability to block serotonin reuptake. In lab studies, its binding affinity for the serotonin transporter is greater than 10,000 nM, which in pharmacology terms means it barely interacts with it at all. For comparison, even atomoxetine (Strattera), which is classified as a pure norepinephrine reuptake inhibitor, has more serotonin transporter activity than Qelbree does.
What Qelbree does instead is influence serotonin indirectly. It blocks one type of serotonin receptor and activates another, which together appear to reduce the inhibitory signals that normally keep serotonin neurons in check. The end result is that serotonin levels rise in the prefrontal cortex (the brain region most involved in attention and impulse control), but through a completely different pathway than SNRIs use. On the norepinephrine side, Qelbree is a moderate reuptake inhibitor, meaning it does block norepinephrine from being recycled, but with less potency than drugs like atomoxetine.
This combination of indirect serotonin modulation and moderate norepinephrine reuptake inhibition is why researchers coined the term “serotonin-norepinephrine modulating agent” to describe it. It touches both chemical systems, but not in the way an SNRI does.
What Qelbree Is Approved For
The FDA approved Qelbree in 2021 for the treatment of ADHD in children and adolescents aged 6 to 17. It has since been approved for adults as well. It is a non-stimulant, which makes it an option for people who cannot tolerate stimulant medications or who have conditions that make stimulants risky, such as a history of substance use or certain heart conditions.
Qelbree is taken once daily as an extended-release capsule. For children aged 6 to 11, the starting dose is 100 mg, which can be increased weekly in 100 mg steps up to a maximum of 400 mg. Teens aged 12 to 17 and adults start at 200 mg, with a maximum of 400 mg for teens and 600 mg for adults. The dose is typically adjusted based on how well symptoms improve and how the medication is tolerated.
Common Side Effects
The side effect profile reflects Qelbree’s unique mechanism and differs somewhat between children and adults. In pediatric clinical trials involving over 800 patients, the most common side effects were sleepiness (16% vs. 4% on placebo), headache (11%), decreased appetite (7%), fatigue (6%), stomach pain (5%), and nausea (5%). Insomnia affected about 4% of children.
Adults tend to experience a different pattern. Insomnia was the most frequent issue in adult trials, affecting 23% of patients compared to 7% on placebo. Headache (17%), nausea (12%), fatigue (12%), decreased appetite (10%), and dry mouth (10%) were also common. Adults were more likely to report constipation, dizziness, and a faster heart rate than children were.
The shift from sleepiness being the top complaint in kids to insomnia being the top complaint in adults is notable. If you’re starting Qelbree and finding that it disrupts your sleep, that’s a recognized effect worth discussing with your prescriber, not necessarily a sign that the medication isn’t working.
How It Compares to Other Non-Stimulant ADHD Medications
The most direct comparison is with atomoxetine (Strattera), the other well-known non-stimulant for ADHD. Atomoxetine is a potent norepinephrine reuptake inhibitor that works in the nanomolar range, meaning it binds very tightly to the norepinephrine transporter. Qelbree’s binding is considerably weaker. However, atomoxetine does not interact meaningfully with serotonin receptors the way Qelbree does. Interestingly, even though atomoxetine occupies more than 85% of serotonin transporters in brain imaging studies, it does not actually increase serotonin levels in the prefrontal cortex in animal studies. Qelbree, despite having almost no serotonin transporter activity, does increase serotonin in that region through its receptor-level effects.
This distinction may explain why some people respond better to one medication than the other, though head-to-head clinical trials comparing the two are limited.
A Drug Interaction Worth Knowing About
Qelbree inhibits a liver enzyme called CYP1A2, which your body uses to break down caffeine among other substances. This means caffeine can build up to higher-than-normal levels in your system while you’re taking Qelbree, potentially amplifying jitteriness, insomnia, nausea, and a racing heart. If you’re a regular coffee or energy drink consumer and you start Qelbree, you may need to cut back on caffeine or pay closer attention to how it affects you. This enzyme interaction also applies to certain other medications, so it’s worth making sure your prescriber has a full list of what you take.